Company / R&D Expense
Viking Therapeutics, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$345.0M
FY2025
5-year range
$31.9M / $345.0M
FY2021-FY2025
Trend
+239.4%
vs FY2024
Sector context
#49 of 210
Health Care
What the data says
R&D Expense changed +239% YoY in FY2025, a notable deviation from the 9-year average annual change of +67%.
Based on SEC 10-K filings.
$345M in FY2025 with a 5-year CAGR of +71.0%. Top quartile in the Health Care sector.
Improved from $45M to $345M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +97.2%
- 5-Year CAGR
- +71.0%
- 10-Year CAGR
- -
Sector benchmark
Top 23% in Health CareTop 23% of 210This company $345.0M Sector average $644.1M
▼
-46.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +71.0%, indicating consistent growth.
- In FY2025, r&d expense increased 239.4% year-over-year.
- Ranks #49 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $345.0M | +239.4% |
| FY2024 | $101.6M | +126.0% |
| FY2023 | $45.0M | +0.0% |
| FY2022 | $45.0M | +40.9% |
| FY2021 | $31.9M | +35.5% |
| FY2020 | $23.6M | +23.7% |
| FY2019 | $19.0M | +38.6% |
| FY2018 | $13.7M | +0.0% |
| FY2017 | $13.7M | +97.2% |
| FY2016 | $7.0M | -68.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026